ScholarWorks@Gyeongsang National University

Browsing by Lee, Jong-SeokAuthor

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
전체 가 나 다 라 마 바 사 아 자 차 카 타 파 하

Showing results 1 to 12 of 12

SCIESCOPUS
A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitorsopen access

Cho, Byoung Chul; Han, Ji-Youn; Kim, Sang-We; Lee, Ki Hyeong; Cho, Eun Kyung; Lee, Yun-Gyoo; Kim, Dong-Wan; Kim, Joo-Hang; Lee, Gyeong-Won; Lee, Jong-Seok, et al.

ArticleIssue Date2022CitationJOURNAL OF THORACIC ONCOLOGY, v.17, no.4, pp 558 - 567PublisherELSEVIER SCIENCE INC
SCISCIESCOPUS
A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy

Ahn, Jin Seok; Lee, Ki Hyeong; Sun, Jong-Mu; Park, Keunchil; Kang, Eun-Suk; Cho, Eun Kyung; Lee, Dae Ho; Kim, Sang-We; Lee, Gyeong-Won; Kang, Jin-Hyoung, et al.

ArticleIssue Date2013CitationLUNG CANCER, v.82, no.3, pp 455 - 460PublisherELSEVIER IRELAND LTD
SCIESCOPUS
Combination chemotherapy with irinotecan and cisplatin in elderly patients (>= 65 years) with extensive-disease small-cell lung cancer

Kim, Hoon-Gu; Lee, Gyeong-Won; Kang, Jung Hun; Kang, Myung-Hee; Hwang, In-Gyu; Kim, Seok Hyun; Hahm, Jong Ryeal; Jeong, Yi Yeong; Kim, Ho-Cheol; Lee, Jong Duk, et al.

ArticleIssue Date2008CitationLUNG CANCER, v.61, no.2, pp 220 - 226PublisherELSEVIER IRELAND LTD
SCIESCOPUS
ctDNA resistance landscape of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI).

Han, Ji-Youn; Ahn, Myung-Ju; Kim, Sang-We; Lee, Ki Hyeong; Cho, Eun Kyung; Lee, Yun-Gyoo; Kim, Dong-Wan; Kim, Joo-Hang; Lee, Jong-Seok; Lee, Gyeong-Won, et al.

ArticleIssue Date2020CitationJournal of Clinical Oncology, v.38, no.15PublisherAmerican Society of Clinical Oncology
SCIESCOPUS
Efficacy and safety of lazertinib 240 mg as the clinical dose in patients with EGFR T790M mutant NSCLC: Data from a phase I/II study.

Lee, Ki Hyeong; Ahn, Myung-Ju; Han, Ji-Youn; Kim, Sang-We; Cho, Eun Kyung; Lee, Yun-Gyoo; Kim, Dong-Wan; Kim, Joo-Hang; Lee, Jong-Seok; Lee, Gyeong-Won, et al.

ArticleIssue Date2020CitationJournal of Clinical Oncology, v.38, no.15PublisherAmerican Society of Clinical Oncology
SCIESCOPUS
Fixed-dose rate infusion of gemcitabine and weekly cisplatin in elderly or poor performance status patients with unresectable non-small cell lung cancer

Lee, Gyeong-Won; Kang, Myung-Hee; Kim, Hoon-Gu; Kang, Jung Hun; Kim, Seok Hyun; Cho, Yu Ji; Jeong, Yi Yeong; Kim, Ho-Cheol; Lee, Jong Duk; Hwang, Young Sil, et al.

ArticleIssue Date2009CitationCANCER CHEMOTHERAPY AND PHARMACOLOGY, v.64, no.2, pp 385 - 390PublisherSPRINGER
SCIESCOPUS
Intracranial anti-tumor activity of lazertinib in patients with advanced NSCLC who progressed after prior EGFR TKI therapy: Data from a phase I/II study.

Kim, Sang-We; Ahn, Myung-Ju; Han, Ji-Youn; Lee, Ki Hyeong; Cho, Eun Kyung; Lee, Yun-Gyoo; Kim, Dong-Wan; Kim, Joo-Hang; Lee, Jong-Seok; Lee, Gyeong-Won, et al.

ArticleIssue Date2020CitationJournal of Clinical Oncology, v.38, no.15PublisherAmerican Society of Clinical Oncology
SCIESCOPUS
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study

Ahn, Myung-Ju; Han, Ji-Youn; Lee, Ki Hyeong; Kim, Sang-We; Kim, Dong-Wan; Lee, Yun-Gyoo; Cho, Eun Kyung; Kim, Joo-Hang; Lee, Gyeong-Won; Lee, Jong-Seok, et al.

ArticleIssue Date2019CitationLANCET ONCOLOGY, v.20, no.12, pp 1681 - 1690PublisherELSEVIER SCIENCE INC
SCIESCOPUSKCI
Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset

Lee, Ki Hyeong; Cho, Byoung Chul; Ahn, Myung-Ju; Lee, Yun-Gyoo; Lee, Youngjoo; Lee, Jong-Seok; Kim, Joo-Hang; Min, Young Joo; Lee, Gyeong-Won; Lee, Sung Sook, et al.

ArticleIssue Date2024CitationCancer Research and Treatment, v.56, no.1, pp 48 - 60Publisher대한암학회
SCIESCOPUS
Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301open access

Reungwetwattana, Thanyanan; Cho, Byoung Chul; Lee, Ki Hyeong; Pang, Yong Kek; Fong, Chin Heng; Kang, Jin Hyoung; Lee, Yun-Gyoo; Lim, Chun Sen; Danchaivijitr, Pongwut; Lim, Yueh Ni, et al.

ArticleIssue Date2023CitationJournal of Thoracic Oncology, v.18, no.10, pp 1351 - 1361PublisherElsevier Inc.
SCISCIESCOPUS
Lazertinib, a 3rd generation EGFR-TKI, in patients with EGFR-TKI resistant NSCLC: Updated results of phase I/II Study.

Ahn, Myung-Ju; Han, Ji-Youn; Kim, Sang-We; Lee, Ki Hyeong; Kim, Dong-Wan; Lee, Yun-Gyoo; Cho, Eun Kyung; Lee, Gyeong-won; Lee, Jong-Seok; Kim, Joo-Hang, et al.

ArticleIssue Date2019CitationJournal of Clinical Oncology, v.37, no.15PublisherAmerican Society of Clinical Oncology
SCIESCOPUSKCI
The expression of thymidine phosphorylase in cancer-infiltrating inflammatory cells in stomach canceropen access

Jang, Joung Soon; Lee, Won Sup; Lee, Jong-Seok; Kim, Hwal Woong; Ko, Gyung Hyuck; Ha, Woo Song

ArticleIssue Date2007CitationJOURNAL OF KOREAN MEDICAL SCIENCE, v.22, pp S109 - S114PublisherKOREAN ACAD MEDICAL SCIENCES
1
CONTACT US

RSS_1.0 RSS_2.0 ATOM_1.0

Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0533

COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

BROWSE

한국어